综合移动戒烟计划与尼古丁替代疗法对成年吸烟者的影响:卡塔尔世界杯8强波胆分析试点随机对照试验%A Marler,Jennifer D %A Fujii,Craig A %A Utley,MacKenzie T %A Balbierz,Daniel J %A Galanko,Joseph A %A Utley,David S %+ Pivot健康技术公司，加州圣卡洛斯商业街1010号C室，94070，美国，14157577696，marler@pivot.co %K戒烟%K数字健康%K智能手机%K数字传感器%K一氧化碳%K呼吸传感器%K生物反馈%K移动应用程序%K健康促进%K应用程序%K手机%D背景:吸烟仍然是可预防疾病和死亡的主要原因，强调了对基于证据的解决方案的持续需求。Pivot是一项基于美国临床实践指南的移动戒烟计划，包括个人一氧化碳呼吸传感器;智能手机应用程序;应用内、基于文本的人工指导;尼古丁替代疗法;还有一个适度的网络社区。有前景的支点队列研究为比较评估奠定了基础。目的:本研究旨在比较Pivot和QuitGuide(美国国家癌症研究所基于美国临床实践指南的戒烟智能手机应用程序)之间的参与度、保留度、戒烟态度、吸烟行为和参与者反馈。 Methods: In this remote pilot randomized controlled trial, cigarette smokers in the United States were recruited on the web and randomized to Pivot or QuitGuide. Participants were offered 12 weeks of free nicotine replacement therapy. Data were self-reported via weekly web-based questionnaires for 12 weeks and at 26 weeks. Outcomes included engagement and retention, attitudes toward quitting smoking, smoking behavior, and participant feedback. The primary outcome was self-reported app openings at 12 weeks. Cessation outcomes included self-reported 7- and 30-day point prevalence abstinence (PPA), abstinence from all tobacco products, and continuous abstinence at 12 and 26 weeks. PPA and continuous abstinence were biovalidated via breath carbon monoxide samples. Results: Participants comprised 188 smokers (94 Pivot and 94 QuitGuide): mean age 46.4 (SD 9.2) years, 104 (55.3%) women, 128 (68.1%) White individuals, and mean cigarettes per day 17.6 (SD 9.0). Engagement via mean “total app openings through 12 weeks” (primary outcome) was Pivot, 157.9 (SD 210.6) versus QuitGuide, 86.5 (SD 66.3; P<.001). Self-reported 7-day PPA at 12 and 26 weeks was Pivot, 35% (33/94) versus QuitGuide, 28% (26/94; intention to treat [ITT]: P=.28) and Pivot, 36% (34/94) versus QuitGuide, 27% (25/94; ITT: P=.12), respectively. Self-reported 30-day PPA at 12 and 26 weeks was Pivot, 29% (27/94) versus QuitGuide, 22% (21/94; ITT: P=.32) and Pivot, 32% (30/94) versus QuitGuide, 22% (21/94; ITT: P=.12), respectively. The biovalidated abstinence rate at 12 weeks was Pivot, 29% (27/94) versus QuitGuide, 13% (12/94; ITT: P=.008). Biovalidated continuous abstinence at 26 weeks was Pivot, 21% (20/94) versus QuitGuide, 10% (9/94; ITT: P=.03). Participant feedback, including ease of setup, impact on smoking, and likelihood of program recommendation were favorable for Pivot. Conclusions: In this randomized controlled trial comparing the app-based smoking cessation programs Pivot and QuitGuide, Pivot participants had higher engagement and biovalidated cessation rates and more favorable user feedback at 12 and 26 weeks. These findings support Pivot as an effective, durable mobile smoking cessation program. Trial Registration: ClinicalTrials.gov NCT04955639; https://clinicaltrials.gov/ct2/show/NCT04955639 %M 36257323 %R 10.2196/41658 %U https://mhealth.www.mybigtv.com/2022/11/e41658 %U https://doi.org/10.2196/41658 %U http://www.ncbi.nlm.nih.gov/pubmed/36257323